Neoadjuvant endocrine treatment in primary breast cancer - Review of literature

Breast

Volumn 18, Issue 6, 2009, Pages 339-344

  Mathew, J ^a   Asgeirsson, K S ^a   Jackson, L R ^a   Cheung, K L ^a   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast conservation surgery; Clinical response; Neoadjuvant endocrine treatment

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VOROZOLE;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR REGRESSION;

EID: 71749115448     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.09.012     Document Type: Review

References (52)

1. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
2. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 369 (2007) 559-570
3. Coates A.S., Keshaviah A., Thürlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 5 (2007 Feb 10) 486-492
4. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
5. Makris A., Powles T.J., Ashley S.E., et al. A reduction in requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in breast cancer. Ann Oncol 9 (1998) 1179-1184
6. Markis A., Powles T.J., Kakolyris S., et al. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 85 9 (1999) 1996-2000
7. Petit T., Wilt M., Velten M., et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40 2 (2004) 205-211
8. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
9. van der Hage J.A., van de Velde C.J.H., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19 (2001) 4224-4237
10. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 3 (2005 Feb 2) 188-194
11. Colleoni M., Gelber S., Coates A.S., et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node negative breast cancer. J Clin Oncol 19 (2001) 4141-4149
12. Gianni L., Baselga J., Eiermann W., et al., European Cooperative Trial in Operable Breast Cancer Study Group. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11 24 Pt 1 (2005 Dec 15) 8715-8721
13. Early Breast Cancer Trialists Collaborative Group. 2000 Analysis overview results. Fifth meeting of Early Breast Cancer Trialists Collaborative Group. Oxford, UK; Sep 2000. p. 21-3.
14. Tan S.M., Cheung K.L., Willsher P.C., Blamey R.W., Chan S.Y., and Robertson J.F.R. Locally advanced primary breast tumour: medium-term results of a randomised controlled trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 37 (2001) 2331-2338
15. Robertson J.F., Ellis I.O., and Alston C.W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 28A 4-5 (1992) 908-910
16. Mustacchi G., Ceccherini R., Milani S., et al., Italian Cooperative Group GRETA. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14 3 (2003 Mar) 414-420
17. Hind D., Wyld L., and Reed M.W. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer. Cochrane review. Br J Cancer 96 7 (2007 Apr 10) 1025-1029
18. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomised double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
19. Ellis M.J., Coop A., Singh B., Mauriac L., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1- and /or ErbB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase 111 randomized trial. J Clin Oncol 19 (2001) 3808-3816
20. Koeberle D., and Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 105 Suppl. 1 (2007) 55-66
21. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9 1 (2008) 23-28
22. Dowsett M., Allred C., Knox J., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26 7 (2008 Mar 1) 1059-1065
23. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
24. Semiglazov V., Semiglazov V.V., Ivanov V.G., et al. Anastrazole vs tamoxifen vs combination as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Proc Am Soc Clin Oncol 22 (2003) 880 [Abstract 3538]
25. Cataliotti L, Buzdar AU, Noguchi S. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor positive breast cancer. 2006;106:2095-103
26. Miller W.R., Dixon J.M., and Cameron D.A. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 79 (2001) 103-107
27. Semiglazov V., Kletsel A., Semiglazov E., et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). (ASCO). J Clin Oncol 23 (2005) 530 [Abstract]
28. Semiglazov V., Semiglazov V.V., Ivanov V.G., Ziltzova E.K., et al. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1-4N1-2 M0). Breast Cancer Res Treat 82 Suppl. 1 (2003) [Abstract 111]
29. Chow L.W., Yip A.Y., Loo W.T., Lam C.K., and Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111 1-2 (2008 Jul) 13-17
30. Dixon J.M., Anderson T., and Miller W.R. Phase 11b study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc ASCO (2001) [Abstract 1908]
31. Barnadas A., Gil M., González S., Tusquets I., et al. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 100 3 (2009 Feb 10) 442-449
32. Krainick U, Astner A, Jonat W, et al. Phase 11 study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI). San Antonio; 2003 [Abstract 239]
33. Tubiana-Hulin M., Becette V., Bieche I., et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res 27 4C (2007 Jul-Aug) 2689-2696
34. Harper-Wynne C.L., Sacks N.P.M., Shenton K., et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20 4 (2002) 1026-1035
35. Basi S.K., and Mackey J.R. Anastrozole plus trastuzumab prolongs progression-free survival in postmenopausal patients with HER2-positive and hormone receptor-positive metastatic breast cancer: a review of the TAnDEM study. Breast Diseases: A Year Book Quarterly 18 (2007) 236-237
36. Seo J.H., Kim Y.H., and Kim J.S. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol 63 2 (2009 Jan) 261-266
37. Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 8 (2008 Feb 26) 62
38. Dixon J.M., Renshaw L., Macaskill E.J., et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 113 1 (2009 Jan) 145-151
39. Mathew J., Agrawal A., Asgerisson K., et al. Primary endocrine therapy in locally advanced breast cancers - Nottingham experience. Eur J Surg Oncol 33 (2007) 1095-1096 [Abstract]
40. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110 (2007) 244-254
41. Singletary S.E., Shallenberger R., and Guinee V.F. Breast cancer in the elderly. Ann Surg 218 5 (1993) 667-671
42. Busch E., Kemeny M., Fremgen A., et al. Patterns of breast cancer care in the elderly. Cancer 78 1 (1996) 101-111
43. McCarty Jr. K.S., Silva J.S., Cox E.B., et al. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg 197 (1983) 123-127
44. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23 1 (2005 Jan 1) 41-48
45. Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24 7 (2006 Mar 1) 1037-1044
46. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., and Miller W.R. The effects of neoadjuvant anastrozole (arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6 6 (2000) 2229-2235
47. Dixon J.M., Love C.D., Bellamy C.O., Cameron D.A., Leonard R.C., Smith H., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66 3 (2001) 191-199
48. Mieog J.S.D., van der Hage J.A., and van de Velde C.J.H. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94 10 (2007) 1189-1200
49. Thomas J.S., Julian H.S., Green R.V., Cameron D.A., and Dixon M.J. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 51 2 (2007 Aug) 219-226
50. Milla-Santos A., Milla L., Calvo N., et al. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res 24 2C (2004 Mar-Apr) 1315-1318
51. Bharagva R., Striebel J., Onisko A., et al. Ki-67 labeling index in breast carcinoma: an immunohistochemical study with correlation to molecular subtypes. J Clin Oncol 26 May 20 Suppl. (2008) [Abstract 22107]
52. Dowsett M., Smith I.E., Ebbs S.R., et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11 Suppl. (2005) 951-958